Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
about
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapyDarbepoetin alfa (Aranesp)Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapyDarbepoetin alfa: a novel erythropoiesis-stimulating protein.Standards of care for anemia management in oncology: focus on lung carcinoma.An overview of the pharmacokinetic disposition of darbepoetin alfa.Darbepoetin alfa: a review of its use in patients with cancer.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Epoetin beta in oncology: examining the current evidence.Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.Impact of long-acting growth factors on practice dynamics and patient satisfaction.
P2860
Q28362982-414B11CD-823B-49B0-A449-E483489541D4Q34116738-356220B0-88B6-41B9-B731-8648BDC3C13EQ34222508-4D4BABA5-50DB-4C28-A41A-0E43ADCAF63EQ34709820-6BDA98E8-329A-4F5C-9A05-28AA211B5C9FQ34810857-C9990566-3691-45C2-B8D6-35C1C76C75E6Q34834816-4C1CA782-B620-4697-946D-00664CEF86A0Q34983303-073D5FE7-694B-4752-9B5C-C5BBBF173459Q35166812-C912D3A4-5458-4840-A1DF-D55D9499E0D3Q36429666-AF630692-46EB-4E5F-BEB0-20B4A656E212Q36624004-5D83C2B0-858B-4719-B0E9-41CB1228014CQ36974670-5C1D6D16-6B01-4C58-B5D1-19418C21D65EQ37385389-FD2BA6B3-4B0C-4939-B907-14D087E51688Q38126361-D4C01D75-2608-4745-92C5-80A38A99AC15Q41892226-ECED008A-6658-4C2D-8B39-3655C202BAF7Q42006796-82834C8F-4D0E-48A3-868F-55ADC830EBD6Q44899669-DC676EDE-01AC-4C4F-AC1B-52D337AD2AEC
P2860
Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@ast
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@en
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@nl
type
label
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@ast
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@en
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@nl
prefLabel
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@ast
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@en
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of novel eryt ...... r patients: preliminary report
@en
P2093
A C Heatherington
A J Mercer
J Schuller
P2860
P2888
P356
10.1054/BJOC.2001.1747
P407
P478
84 Suppl 1
P577
2001-04-01T00:00:00Z
P5875
P6179
1004332627